In a preclinical immunoactive ovarian cancer mouse model, AAV gene therapy vectors were used to express 3TSR alone or in combination with the CD47-binding peptide of TSP-1 to assess its effect on tumor development and survival. This evidence concerns the gene THBS1 and ovarian cancer.